CRP and diabetes mellitus: Treatment with either rosiglitazone (4–8 mg daily for 8 to 26 weeks) or pioglitazone (45 mg daily for 3 months) significantly reduced C-reactive protein (CRP) levels in patients with diabetes [47, 48] as well as in non-diabetic patients with coronary artery disease [49] and rheumatoid arthritis [50].